Rivaroxaban作用功效

Rivaroxaban effects:

Rivaroxaban was jointly developed by Bayer Pharmaceuticals of Germany and Johnson & Johnson of the United States.

In October 2008, Rivaroxaban was approved for marketing in Canada and the European Union under the trade name Xarelto.

On July 1, 2011, the FDA approved Rivaroxaban for the prevention of deep vein thrombosis in patients undergoing knee or hip replacement surgery.

Rivaroxaban is the world's first oral direct factor Xa inhibitor that can highly selectively and competitively inhibit free and bound factor It has the characteristics of high bioavailability, wide spectrum of disease treatment, stable dose-effect relationship, convenient oral administration and low risk of bleeding.

Rivaroxaban is also a drug used to prevent and treat venous thrombosis. Clinically, it is mainly used to prevent the formation of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients after hip and knee replacement surgery. It can also be used to prevent stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation, and reduce the risk of recurrence of coronary syndrome.

A dose-dependent inhibition of factor Xa activity by Rivaroxaban has been observed in humans. Rivaroxaban's effect on prothrombin time (PT) has a dose-effect relationship. If NeopLastin® is used for content measurement, it is closely related to plasma concentration (correlation coefficient is 0.98). Different results may occur with other reagents. Reading the PT should be completed within seconds because the International Normalized Ratio (INR) is calibrated and validated only for coumarins and not for other anticoagulants. In patients undergoing major orthopedic surgery, 5/95 (percentile) PT was 13 to 25 seconds 2 to 4 hours after taking the tablet (when the effect was strongest) (baseline value before surgery was 12 to 15 seconds).